Navigation Links
Malignant Mesothelioma – A New Genetic Revelatio

Malignant mesothelioma is a very aggressive tumor which is found resistant to most of the treatment, which is increasing in frequency throughout the world. The main causative agents for the development of Malignant mesothelioma is exposure to asbestos, recently a virus, simian virus 40 (SV40) is also found to be a causative agent for development of this tumor.

Many people with malignant mesothelioma have worked or lived in places where they inhaled or swallowed asbestos. After being exposed to asbestos, it usually takes a long time for malignant mesothelioma to occur. In a report in the current issue of Lancet it is reported that mesothelioma has an unusual molecular pathology with loss of tumour suppressor genes being the predominant pattern of lesions, especially the P16INK4A, and P14ARF, and NF2 genes, rather than the more common p53 and Rb tumour suppressor genes.

In a previous report from earlier this month from the UC Davis Department of Public Health Sciences suggested that that risks from exposure to naturally occurring asbestos though low was real and was to be taken seriously. Marc Schenker, professor and chair of and the study's senior author said:"This study provides important supportive evidence that naturally occurring asbestos causes mesothelioma - and public efforts should now shift to understanding the risk and how we can protect people from this preventable malignancy."

Mesothelioma kills about the same number of Americans each year as passive smoking. About 2,500 people a year die from mesothelioma in the United States, according to National Institute of Occupational Safety and Health statistics.

Mortality in Britain from Mesethelioma rose from 153 deaths in 1968 to 1,848 in 2001 and is still increasing and according to a study reported in Feb this year from UK, the rate will begin to decline by 2015. The study predicted that the peak in mortality in UK, will come between 2011 and 2015, the highest
'"/>




Page: 1 2 3

Related medicine news :

1. Malignant Mesothelioma – A New Genetic Revelation
2. Malignant virus in polio vaccine combined to Cancer
3. Experimental Therapy Effective Against Malignant Melanoma in Horses
4. Protein Involved In Embryo Formation Found In Malignant Cells
5. Novel Suicide Gene Therapy Used to Treat Malignant Brain Tumors
6. Detection of Malignant Breast Tumors Made Simpler and More Effective
7. Malignant Mesothelioma – A New Genetic Revelation
8. ‘Mesothelioma’- Trouble Under the Asbestos Rof
9. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
10. Genetic influence in menopause
11. Genetics and cholesterol levels

Post Your Comments:
(Date:11/9/2009)...-- For the third consecutive year, the Barbara Ann... preferred hospital for cancer care in southeast M...earch Corporation. ,, (Logo: http://www.news..., The annual survey was conducted through an email...009. Survey respondents were the primary healthcar...
(Date:11/9/2009)..., however , , MONDAY, Nov. 9 (HealthDa...se breasts have a higher risk of cancer recurrence...reast density has already been linked with an incr...s have suspected that very dense breasts may also ...urrence at the site of the original cancer after l...
(Date:11/9/2009)...ewswire/ -- New Mayo Clinic research has found tha...cally reduces patient hospital stay and recovery t...at the North Central Section of the American Urolo...o: http://www.newscom.com/cgi-bin/prnh/20090105/... and video resources, including excerpts from an i...
(Date:11/9/2009)...re for Preteen Son - ,, PHILADELPHIA, Nov. 9 ... with cancer, the hopeful news is that pediatric s...Among the bad news -- treatments that enable survi...d with cancer who have reached puberty currently h...fore undergoing cancer treatment, they may have th...
(Date:11/9/2009)... WHAT: All PETCO stores nationwide will host a...ated by specially trained in-store nutrition, .... During the 30-minute, workshop, pe...f, their dogs and cats, have a chance... nutrition, receive an assessment of their individ...
Breaking Medicine News(10 mins):Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 2Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4
...try,s Leading Study Tool to Expand Profile with Ar... Prep, the massage,industry,s leading study progra... massage school graduates. Beginning in 2008, Area... Prep guarantees passage of the rigorous NCETM and...
...sing Fourth Quarter & Full-Year 2007 Financial Res... 11, 2008, Presenting at the UBS Global Healthcar... February 12, 2008, CINCINNATI, Jan. 28 ... community events., Fourth Quarter & Full-Year 20...
...e number of Russian women who smoke has more than ...cording to new research. , In 1992, seven per cen...by 2003. In the same period, the number of men who...on of the previously state owned tobacco industry ...
...w York, New York The Cancer Research Institute (C...he Cancer Vaccine Consortium, a program of the Sab...borative, a program of the Cancer Research Institu...ed voice in the cancer vaccine field and provides ...
...LE, Jan. 28 Results from Milliman,s third annual,... U.S. variable annuity,(VA) carriers indicate that...some form of GLB., Total sales of VAs that offere...up to 95% during the first,half of 2007, demonstra...
...DO, Fla., Jan. 28 MEDai, Inc., headquartered in,O...hcare solutions,announced that its longstanding Pi... Diego, CA, was awarded the 2007 Malcolm Baldrige ...ce. Congress,established the program in 1987 to re...
Other Medicine News:Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 2Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 3Health News:Milliman Survey Confirms Continued Dominance of Guarantees in Variable Annuity Retirement Income Products 2Health News:Milliman Survey Confirms Continued Dominance of Guarantees in Variable Annuity Retirement Income Products 3Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 2Health News:MEDai Client Named Recipient of 2007 Malcolm Baldrige National Quality Award 3
(Date:11/9/2009)..., Mass., Nov. 9 Caliper ...ovider of tools and services for drug discovery an... Caliper Discovery Alliances and Services (CDAS) u...$1.8 million under its contract with the Environme... screening program. This new task order increases...
(Date:11/6/2009)...Wash., Nov. 6 SCOLR Phar...sults for the three and nine months ended Septembe...a,s President and CEO, said, "We continue to advan...uprofen formulation. Several potential partners ha...nel and external resources as they evaluate the po...
(Date:11/6/2009)...N, Mass., Nov. 6 DUSA Ph...ermatology company that is developing and marketin...ther products focused on patients with common skin...nd Chief Executive Officer, will present a corpora...ummit 2009 on Tuesday, November 10, 2009 at 10:00 ...
Breaking Medicine Technology:Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10ViroPharma Announces Appointment of Frank Baldino Jr Ph D to Board of Directors 48170 1ViroPharma Announces Appointment of Frank Baldino Jr Ph D to Board of Directors 48170 2ViroPharma Announces Appointment of Frank Baldino Jr Ph D to Board of Directors 48170 3New Nutrisystem Works 28TM 29 Offers Corporate America New Weapon in the Fight Against Obesity 48167 1New Nutrisystem Works 28TM 29 Offers Corporate America New Weapon in the Fight Against Obesity 48167 2New Nutrisystem Works 28TM 29 Offers Corporate America New Weapon in the Fight Against Obesity 48167 3New Nutrisystem Works 28TM 29 Offers Corporate America New Weapon in the Fight Against Obesity 48167 4
...ering Cancer Center Investigators to Assess BSI-20...r Patients -, BRISBANE, Calif., May 8 BiPar Scie...2 clinical trial programs for its lead,product, BS...clinical trial,of BSI-201 that BiPar has launched ... in breast and brain cancer., The company is eval...
...ferred Induction Dosing Regimen, SEATTLE, May 7 ...y announced that its partner, Wyeth Pharmaceutical...d patient dosing in the next,Phase 2b clinical tri...s,(RA). In collaboration with Trubion, Wyeth Pharm...r CD20-directed products., The randomized, parall...
Other Medicine Technology:BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4
Human Growth Hormone EIA Endocrine Function 025-BC-1033
...of pancreatic b-cell function is not only of use i...l history of diabetes mellitus, but is also releva...choice of treatment. Peripheral insulin levels ca... the large and variable uptake from the portal cir...
Anti-Gliadin IgG & IgA (Ab) EIA Gastrointestinal Markers 027-GD77 Celiac Disease Food Allergy
...n enzymeimmunoassay for the quantitation of 25-OH ...lasma. Calibrators, controls and samples are dilut...es are incubated in microtitre wells which are coa...for 2 hours at room temperature before aspiration ...
Medicine Products: